Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2007

View Archived Issues

Targeting TRPV1 for the treatment of type 1 diabetes

Sirolimus to be tested in clinical trial for ALPS / News in Context

Novartis reports positive preclinical results of novel Nurr1 activator

Targepeutics developing targeted molecular therapies for cancer

NEOSH-101 increases hair growth significantly in men with androgenetic alopecia

Refrigerated formulation of FluMist receives FDA approval

Depression and anxiety compound TC-2216 begins phase I trial

New phase II study evaluates R-788 in ITP

Interim analysis clears pivotal study of pralatrexate to continue

Phase II/III pain program outlined for Anesiva's 4975

Alkermes and Lilly sign manufacturing agreement for AIR Inhaled Insulin

Genentech and Seattle Genetics sign worldwide license agreement for SGN-40

Bayer and Berlex combine businesses in Canada

Boehringer Ingelheim and Ablynx to develop Nanobodies for Alzheimer's

New phase II trial studies nemonoxacin for CAP

ZEN-012 begins phase I study in solid tumors and lymphoma

Patents disclose therapeutic agents for schizophrenia, depression and other psychological disorders

Novel antiinfective agents disclosed in recent AstraZeneca and Novozymes patents

New vitamin D3 receptor agonists prepared and tested at Chugai

CAT grants iCo license to CAT-213

Pierre Fabre acquires UCB's OTC business in certain countries

deCODE genetics updates development programs

European approval for once-weekly NeoRecormon

Orphan drug designation for PV-10 in metastatic melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...